Next 10 |
(NewsDirect) Aura Energy Ltd (ASX:AEE, AIM:AURA) MD Dave Woodall speaks with Proactive soon after announcing the company has raised A$10 million via a share placement at A$0.185 per share to advance development across the company’s project portfolio. The placement was supported by exis...
(NewsDirect) Aura Energy Limited (ASX: AEE, AIM: AURA) CEO Dave Woodall responds to a recent report that the Industry Committee of the Swedish parliament has voted to reject a number of private members’ motions supporting an immediate lifting of the ban on uranium mining in Sweden. He ...
2023-03-15 17:12:04 ET Aura Biosciences press release ( NASDAQ: AURA ): FY GAAP EPS of -$1.96 misses by $0.02 . As of December 31, 2022, Aura had cash and cash equivalents and marketable securities totaling $188.8 million. Aura believes its current cash and cash equiva...
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track ...
Oncology-focused biotech Aura Biosciences ( NASDAQ: AURA ) added ~3% pre-market Thursday after updating interim results from the company’s Phase 2 trial for eye cancer therapy Belzupacap Sarotalocan (bel-sar) in choroidal melanoma. The study is designed to evaluate bel-sar,...
Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of positive interim Phase 2 safety and efficacy data of be...
(NewsDirect) Aura Energy Ltd (ASX:AEE, AIM:AURA) MD Dave Woodall discusses with Proactive a 52% increase in measured and indicated resources at the Tiris Uranium Project in Mauritania. He says the immediate focus is now to work with in-country stakeholders, offtake providers, investors and fi...
Shares of clinical-stage biotech company Aura Biosciences (NASDAQ: AURA) were up 11.2% as of Thursday afternoon, according to data provided by S&P Global Market Intelligence . The stock closed last week at $10.13 and climbed to as high as $12.31 on Tuesday. Aura's 52-week low ...
Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 6,700,000 shares of its c...
Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. All shar...
News, Short Squeeze, Breakout and More Instantly...
Aura Biosciences Inc. Company Name:
AURA Stock Symbol:
NASDAQ Market:
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidenc...
Aura Biosciences Inc (NASDAQ: AURA) shares are trading lower by 34.7% to $7.18 Tuesday afternoon after the company announced pricing of its pu...
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2...